NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$142.7m

Last Updated

2021/05/15 23:35 UTC

Data Sources

Company Financials +

Executive Summary

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. More Details


Snowflake Analysis

Concerning outlook with weak fundamentals.


Similar Companies

Share Price & News

How has Progenity's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PROG is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: PROG's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-13.2%

PROG

-2.0%

US Healthcare

-1.7%

US Market


1 Year Return

n/a

PROG

39.3%

US Healthcare

50.8%

US Market

Return vs Industry: Insufficient data to determine how PROG performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how PROG performed against the US Market.


Shareholder returns

PROGIndustryMarket
7 Day-13.2%-2.0%-1.7%
30 Day-30.8%4.1%-1.2%
90 Day-57.9%14.7%0.4%
1 Yearn/a41.1%39.3%53.3%50.8%
3 Yearn/a59.9%53.4%61.5%51.4%
5 Yearn/a108.8%93.2%125.9%100.7%

Long-Term Price Volatility Vs. Market

How volatile is Progenity's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Progenity undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Progenity is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Progenity has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Progenity forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

10.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PROG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PROG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PROG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PROG's revenue (18.3% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: PROG's revenue (18.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PROG's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Progenity performed over the past 5 years?

4.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: PROG is currently unprofitable.

Growing Profit Margin: PROG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PROG's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PROG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PROG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (59.7%).


Return on Equity

High ROE: PROG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Progenity's financial position?


Financial Position Analysis

Short Term Liabilities: PROG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PROG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PROG has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PROG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PROG has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PROG has less than a year of cash runway if free cash flow continues to reduce at historical rates of 40.5% each year


Dividend

What is Progenity current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PROG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PROG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PROG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PROG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PROG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Harry Stylli (58 yo)

2.75yrs

Tenure

US$5,753,322

Compensation

Dr. Harry Stylli, MBA, PhD is the Founder of Progenity, Inc. and serves as its Chief Executive Officer and Chairman of the Board since August 2018. Dr. Stylli was Executive Chairman of Progenity, Inc. from...


CEO Compensation Analysis

Compensation vs Market: Harry's total compensation ($USD5.75M) is above average for companies of similar size in the US market ($USD540.11K).

Compensation vs Earnings: Harry's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PROG's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: PROG's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: PROG only recently listed within the past 12 months.


Top Shareholders

Company Information

Progenity, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Progenity, Inc.
  • Ticker: PROG
  • Exchange: NasdaqGM
  • Founded: 2010
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$142.720m
  • Shares outstanding: 60.47m
  • Website: https://www.progenity.com

Number of Employees


Location

  • Progenity, Inc.
  • 4330 La Jolla Village Drive
  • Suite 200
  • San Diego
  • California
  • 92122
  • United States

Listings


Biography

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women ear...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 23:35
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.